A NOD/SCID Tumor Model for Human Ovarian Cancer That Allows Tracking of Tumor Progression Through the Biomarker Sp17
Overview
Pathology
Authors
Affiliations
No experimental animal model employing a primary human ovarian carcinoma (OC) cell line is presently available that tracks the progression of this cell line with an identifiable marker. This hinders investigations related to developing new approaches for treating OC. Here, we describe the development of a tumor model in NOD/SCID mice for human OC that makes use of the endogenously expressed tumor specific sperm protein 17 (Sp17) cancer testis antigen. In this model, human SKOV-3 OC cell lines were intra-peritoneally seeded. Subsequently viable SKOV-3 cells were recovered from primary organ cell cultures from the liver ovaries, abdomen, and ascitic fluid, and their presence was confirmed by the detection of Sp17 mRNA by RT-PCR and Sp17 protein by immunocytochemistry and FACS analysis. When SKOV-3 tumor cells were administered intravenously the mice developed primarily lung tumor foci. This model makes it possible to evaluate new immunotherapeutic strategies for the treatment of human OC based on the biomarker Sp17.
Tu Z, Peng J, Long X, Li J, Wu L, Huang K Front Immunol. 2022; 13:844736.
PMID: 35592314 PMC: 9110779. DOI: 10.3389/fimmu.2022.844736.
Mirandola L, Chiriva-Internati M, Bresalier R, Piccotti L, Grizzi F, Marincola F J Transl Med. 2019; 17(1):424.
PMID: 31878933 PMC: 6931250. DOI: 10.1186/s12967-019-02163-4.
Schutt C, Mirandola L, Figueroa J, Nguyen D, Cordero J, Bumm K Oncotarget. 2017; 8(59):100280-100287.
PMID: 29245977 PMC: 5725019. DOI: 10.18632/oncotarget.22213.
Mirandola L, Pedretti E, Figueroa J, Chiaramonte R, Colombo M, Chapman C Oncotarget. 2017; 8(43):74378-74390.
PMID: 29088794 PMC: 5650349. DOI: 10.18632/oncotarget.20102.
Ma N, Liu L, Min J, Wang J, Jiang W, Liu Y Clin Exp Metastasis. 2011; 28(8):765-78.
PMID: 21785830 DOI: 10.1007/s10585-011-9408-6.